Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.

Pharmacopsychiatry - 1 Nov 2014

Proft F, Kopf J, Olmes D, Hempel S, Schmidt B, Riederer P, Deckert J, Pfuhlmann B, Reif A, Unterecker S

Abstract excerpt

OBJECTIVE: The effects of genetic variants in genes encoding the target structures of antidepressants on the therapeutic efficacy of antidepressant drugs have been investigated with unconclusive results. One possible confounding factor in most studies was the fact that drug serum concentrations had not been determined. METHODS: Within a clinical setting, 56 inpatients suffering from depressive episodes in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Bipolar Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclohexanols

Share to Depressive Disorder, Major

Share to Norepinephrine Plasma Membrane Transport Proteins

Share to Selective Serotonin Reuptake Inhibitors

Share to Serotonin Plasma Membrane Transport Proteins

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 25295552
DOI: 10.1055/s-0034-1390412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.PMID 25295552Read ↗

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder.Semantic proximity Read ↗

Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.Semantic proximity Read ↗

No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.Semantic proximity Read ↗

SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.Semantic proximity Read ↗

Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain.Semantic proximity Read ↗

Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.Semantic proximity Read ↗

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.